Melanoma vaccines;Vacunas de melanoma

Dermatology Online Journal

Volumn 6, Issue 1, 2000, Pages 159-214

  Naylor, Mark F ^a  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIBODY; ANTIGEN; BIOLOGICAL RESPONSE MODIFIER; COMPLEMENT; CYTOKINE; DACARBAZINE; DNA VACCINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 2; LIVE VACCINE; MELANOMA VACCINE; RECOMBINANT VACCINE;

ADVANCED CANCER; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER PREVENTION; CANCER RECURRENCE; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOTOXICITY; DENDRITIC CELL; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SCREENING; DRUG UTILIZATION; FEVER; GENE DELIVERY SYSTEM; GENETIC CODE; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNIZATION; IMMUNOGENICITY; MALAISE; MELANOMA; MELANOMA CELL; MOLECULAR RECOGNITION; OPSONIZATION; PAIN; PRURITUS; REVIEW; T LYMPHOCYTE; TOXICITY; TUMOR CELL; TUMOR IMMUNITY; VACCINATION; VITILIGO;

EID: 3242696050     PISSN: 10872108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (4)

1. Ollila DW, Kelley MC, Gammon G, Morton DL. Overview of melanoma vaccines: active specific immunotherapy for melanoma patients. Semin Surg Oncol 1998;14(4):328-36. PubMed
2. Berd D, Kairys J, Dunton C, Mastrangelo MJ, Sato T, Maguire HC Jr. Autologous, hapten-modified vaccine as a treatment for human cancers. Semin Oncol 1998;25(6):646-53. PubMed
3. Soiffer R, Lynch T, Mihm M, Jung K, Rhuda C, Schmollinger JC, Hodi FS, Liebster L, Lam P, Mentzer S, Singer S, Tanabe KK, Cosimi AB, Duda R, Sober A, Bhan A, Daley J, Neuberg D, Parry G, Rokovich J, Richards L, Drayer J, Berns A, Clift S, Dranoff G, et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci U S A 1998;95(22):13141-6. PubMed
4. Schreiber S, Kampgen E, Wagner E, Pirkhammer D, Trcka J, Korschan H, Lindemann A, Dorffner R, Kittler H, Kasteliz F, Kupcu Z, Sinski A, Zatloukal K, Buschle M, Schmidt W, Birnstiel M, Kempe RE, Voigt T, Weber HA, Pehamberger H, Mertelsmann R, Brocker EB, Wolff K, Stingl G. Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: outcome of a phase I study. Hum Gene Ther 1999;10(6):983-93. PubMed